By Candice Choi

Don’t even think of putting the mask away anytime soon.

Despite the expected arrival of COVID-19 vaccines in just a few weeks, it could take several months — probably well into 2021 — before things get back to something close to normal in the U.S. and Americans can once again go to the movies, cheer at an NBA game or give Grandma a hug.

The first, limited shipments of the vaccine would mark just the beginning of what could be a long and messy road toward the end of the pandemic that has upended life and killed more than a quarter-million people in the U.S. In the meantime, Americans are being warned not to let their guard down.

“If you’re fighting a battle and the cavalry is on the way, you don’t stop shooting; you keep going until the cavalry gets here, and then you might even want to continue fighting,” Dr. Anthony Fauci, the nation's top infectious-disease expert, said last week.

This week, AstraZeneca became the third vaccine maker to say early data indicates its shots are highly effective. Pfizer last week asked the U.S. Food and Drug Administration for emergency authorization to begin distributing its vaccine, and Moderna is expected to do the same any day. Federal officials say the first doses will ship within a day of authorization.

But most people will probably have to wait months for shots to become widely available. The Pfizer and Moderna vaccines also each require two doses, meaning people will have to go back for a second shot after three and four weeks, respectively, to get the full protection.

Moncef Slaoui, head of the U.S. vaccine development effort, said on CNN on Sunday that early data on the Pfizer and Moderna shots suggest about 70% of the population would need to be vaccinated to achieve herd immunity — a milestone he said is likely to happen in May.

But along the way, experts say the logistical challenges of the biggest vaccination campaign in U.S. history and public fear and misinformation could hinder the effort and kick the end of the pandemic further down the road.

“It’s going to be a slow process and it’s going to be a process with ups and downs, like we’ve seen already,” said Dr. Bill Moss, an infectious-disease expert at Johns Hopkins University.

SHOTS IN ARMS

Once federal officials give a vaccine the go-ahead, doses that are already being stockpiled will be deployed with the goal of “putting needles in people’s arms” within 24 to 48 hours, said Paul Mango, a U.S. Department of Health and Human Services official involved in the Operation Warp Speed effort to develop COVID-19 vaccines.

Those first shipments are expected to be limited and will be directed to high-risk groups at designated locations, such as front-line health care workers at hospitals.

Federal and state officials are still figuring out exactly how to prioritize those most at risk, including the elderly, prison inmates and homeless people. By the end of January, HHS officials say, all senior citizens should be able to get shots, assuming a vaccine becomes available by the end of 2020.

For everyone else, they expect widespread availability of vaccines would start a couple of months later.

To make shots easily accessible, state and federal officials are enlisting a vast network of providers, such as pharmacies and doctor’s offices.

But some worry long lines won’t be the problem.

“One of the things that may be a factor that hasn’t been discussed that much is: ‘How many will be willing to be vaccinated?’” said Christine Finley, director of Vermont's immunization program. She noted the accelerated development of the vaccine and the politics around it have fueled worries about safety.

Even if the first vaccines prove as effective as suggested by early data, they won’t have much impact if enough people don’t take them.

NO MAGIC BULLET

Vaccines aren’t always effective in everyone: Over the past decade, for example, seasonal flu vaccines have been effective in about 20% to 60% of people who get them.

AstraZeneca, Pfizer, and Moderna say early trial data suggests their vaccine candidates are about 90% or more effective. But those rates could change by the time the studies end.

Also, the definition of “effective” can vary.

Rather than prevent infection entirely, the first COVID-19 vaccines might only prevent illness. Vaccinated people might still be able to transmit the virus, another reason experts say masks will remain crucial for some time.

Another important aspect of vaccines: They can take a while to work.

The first shot of a COVID-19 vaccine might bring about a degree of protection within a couple of weeks, meaning people who get infected might not get as sick as they otherwise would. But full protection could take up to two weeks after the second shot -- or about six weeks after the first shot, said Deborah Fuller, a vaccine expert at the University of Washington.

People who don’t understand that lag could mistakenly think the vaccine made them sick if they happen to come down with COVID-19 soon after a shot. People might also blame the vaccine for unrelated health problems and amplify those fears online.

“All you need is a few people getting on social media,” said Moss of Johns Hopkins University.

There's also the possibility of real side effects. COVID-19 vaccine trials have to include at least 30,000 people, but the chances of a rare side effect turning up are more likely as growing numbers of people are vaccinated.

Even if a link between the vaccine and a possible side effect seems likely, the distribution of shots might not be halted if the risk is deemed small and is outweighed by the benefits, said Dr. Wilbur Chen, a vaccine expert at the University of Maryland.

But Chen said public health officials will need to clearly explain the relative risks to avoid public panic.

Depending on whether the virus mutates in coming years and how long the vaccine’s protection lasts, booster shots, later on, may also be necessary, said Dr. Edward Belongia, a vaccine researcher with the Marshfield Clinic Research Institute in Wisconsin.

Belongia and many others say the coronavirus won’t ever be stamped out and will become one of the many seasonal viruses that sicken people. How quickly will vaccines help reduce the threat of the virus to that level?

“At this point, we just need to wait and see,” Belongia said.

——

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
New Tech Firm PulseForge Looks to Reduce Emissions From Manufacturing
Stan Farnsworth, chief marketing officer at PulseForge, joined Cheddar to talk about his company's debut at CES 2022 and how it plans to innovate the sustainable tech manufacturing space. PulseForge is bringing a new approach to industrial thermal processing, which contributes to 30 percent of global greenhouse gas emissions, according to Farnsworth. "By using 85 percent less energy in the processing of materials through a variety of manufacturing processes, we can make a direct impact in reducing carbon output and reducing carbon footprint associated with manufacturing," he said.
Vaccination Mandate for Crossing U.S. Border to Go Into Effect
The U.S. will be implementing a vaccine mandate for all people entering through its land borders, removing exemptions for "essential" travelers such as truckers, students, and business people. While the Canadian Trucking Alliance argues that the new, stricter rule might exacerbate ongoing auto supply chain issues, some health experts see the potential for helping curb the ongoing pandemic. Anthony Santella, a professor of health administration at the University of New Haven, joined Cheddar to give his take on the updated border crossing restriction. "We can't just focus on one type of travel. We need to ensure that it's clear and consistent across all types of travel," Santella said.
Space VIP Announces NYC's Space Prize Challenge
To encourage and inspire young women to pursue careers in STEAM, or science, technology, engineering, arts, and math, Space VIP has officially launched its New York Space Prize Challenge. Young women enrolled in the public school system within New York's five boroughs and are between the ages of 15 to 18 are welcomed to participate. Executive Director of Space Prize, Kim Macharia, joined Cheddar to discuss more.
Behind Australian Judges Ruling for Allowing Novak Djokovic Deportation
The drama surrounding tennis star Novak Djokovic continues after he was deported from Australia over the weekend due to the nation's COVID-19 vaccine requirements. Djokovic was forced to leave the country on the eve of what was to be his first match in defense of his Australian Open title after three judges ruled in favor of his removal and revealed their reasoning for doing so. Adding to his woes, a law recently passed in France is putting his chances of defending his French Open title in jeopardy. The director of Marist's Center for Sports Communication, Jane McManus, joined Cheddar to discuss the ongoing fallout.
Dept. Of Agriculture 10-Year Plan To Combat Wildfires
The Department of Agriculture has officially unveiled its plan to fight catastrophic wildfires that have devastated parts of the West in the last few years. The department, along with the Forest Service will work to significantly increase fuels and forest health treatments to address the escalating crisis of wildfire danger. Executive Editor of Cipher, a publication by Breakthrough Energy, Amy Harder, joined Cheddar to discuss more.
Non-Drug, Non-Invasive, FDA-Cleared Device to Treat OCD
Brainsway, the medical device company that developed deep TMS, has been conducting clinical trials of the treatment in various psychiatric, neurological, and addiction disorders. Their most recent research suggests that deep TMS is an effective treatment for OCD. Christopher Von Jako, president and chief executive officer of Brainsway, joins Cheddar News to discuss.
Load More